Form 4: ANAPTYSBIO Director Sells Over 20,000 Shares

ANAPTYSBIO Director John P. Schmid sold 20,645 shares of common stock in multiple transactions under a pre-arranged 10b5-1 plan.

Summary

• John P. Schmid, a Director of ANAPTYSBIO, INC. (ANAB), reported the sale of common stock.
• The transactions occurred on March 30, 2026, and were made pursuant to a Rule 10b5-1 pre-arranged trading plan.
• A total of 20,645 shares were sold across three separate transactions.
• The first transaction involved 12,596 shares sold at a weighted average price of $55.7087 per share, with prices ranging from $55.20 to $56.11.
• The second transaction involved 7,527 shares sold at a weighted average price of $56.7002 per share, with prices ranging from $56.20 to $57.19.
• The third transaction involved 522 shares sold at a weighted average price of $57.3989 per share, with prices ranging from $57.21 to $57.92.
• Following these transactions, John P. Schmid beneficially owns 31,622 shares of ANAPTYSBIO common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can be perceived negatively, the disclosure that it was conducted under a Rule 10b5-1 plan mitigates concerns that it is based on new, undisclosed negative information. It is likely for personal financial planning.

Negatives

• A director selling a significant number of shares, even under a pre-arranged plan, can sometimes be perceived by the market as a lack of confidence in the company's near-term prospects.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales by directors, are closely watched by investors for signals regarding management's confidence. While sales under a Rule 10b5-1 plan are pre-scheduled and often for personal financial planning reasons, they still represent a reduction in insider ownership. The market typically scrutinizes the timing and magnitude of such sales relative to company performance and broader industry trends.

Stakeholder Impact

• Shareholders may interpret the director's sale as a slight negative signal, potentially leading to short-term price volatility, although the 10b5-1 plan context reduces the severity of this interpretation.

Key Dates

Recommendation

A single Form 4 filing detailing a director's sale, especially when conducted under a pre-arranged 10b5-1 plan, typically does not warrant a change in investment recommendation. While insider selling is generally monitored, this specific transaction appears to be part of routine financial planning rather than a reaction to new material information. Investors should hold their position and monitor future company developments and broader market trends.

Keywords

ANAPTYSBIO, ANAB, Form 4, Insider Sale, Director Transaction, Stock Sale, 10b5-1 Plan